Application of an angiotensin)converting enzyme inhibitor zofenopril in patients with paroxismal form of atrial fibrillation
https://doi.org/10.18705/1607-419X-2007-13-3-197-201
Abstract
In article the received data of pilot research of application of an angiotensin-converting enzyme inhibitor zofenopril in patients with paroxismal form of atrial fibrillation without structural diseases of heart are submitted. It is shown, that prescription of zofenopril in this category of patients is an effective and safe method of treatment. Probable mechanisms of positive influence of a preparation on current of an arrhythmia are discussed.
About the Author
B. A. Tatarskyi
ФГУ «Федеральный Центр Сердца, Крови и Эндокринологии им. В.А. Алмазова Росмедтехнологии», г. Санкт-
Петербург
Russian Federation
Russian Federation
References
1. Kannel W., Wolf P., Benjamin E. et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.
2.
3. Benajmim E., Levy D., Vaziri S. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study JAMA 1994;171:840-44
4.
5. Кушаковский М.С.. Фибрилляция предсердий (причины, механизмы, клинические формы, лечение и профилактика) Санкт-Петербург 1999; 175
6.
7. Freestone B, Lip G.. Epidemiology and costs of cardiac arrhythmias. In: Lip G. Godtfredsen J (eds).Cardiac Arrhythmias: A Clinical Approach Mosby: Edinburgh 2003; pp 3?24.
8.
9. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: Eur. Heart J., August 1, 2006; 27(16): 1979-2030.
10.
11. Lip G, Tello-Montoliu A. Management of atrial fibrillation. Heart, August 1, 2006; 92(8):1177-1182.
12.
13. Freestone B, Beevers D, Lip G. The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target? J Hum Hypertens 2004; 18: -61?465.
14.
15. Li D, Shinagawa K, Pang L. Effects of angiotensin- converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;10-:2608-261
16.
17. Kober L, Torp-Pedersen C, Carlsen J et al. A clinical trial of the angiotensin converting enzyme inhibitor Trandolapril in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 1995;333:1670-1676.
18.
19. Ueng KC, Tsai TP, Yu WC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: results of a prospective and controlled study. Eur. Heart J. 2003;2-:2090-2098
20.
21. Vermes E, Tardif J, Bourassa M. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003;107:2926-2931.
22.
23. Madrid A, Bueno M, Rebollo J. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-336.
24.
25. Jeff S. Crystal E, Garfinkle M et al. Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Meta-Analysis. J Am Coll Cardiol, 2005; -5:1832-1839.
26.
27. Б.А.Татарский Использование ингибиторов АПФ при лечении пароксизмальной формы фибрилляции предсердий. Российский кардиологический журнал, 2005;.3:58-63.
28.
29. Ehrlich J, Hohnloser S, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence Eur. Heart J., March 1, 2006; 27(5): 512-518.
30.
31. Miller J., Zipes D. Management of the patient with cardiac arrhithmias. A textbook of cardiovascular medicine. Philadelphia: W. B. Saunders company. 2001. P. 731-736.
32.
33. Shi Y, Ducharme A, Nattel S, et al. Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation Cardiovasc Res 2001;52:217-225.
34.
35. Van Wagoner D, Nerbonne J. Molecular basis of electrical remodeling in atrial fibrillation. J. Mol Cell Cardiol. 2000;32:1101-1117.
36.
37. Yu W, Chen S, Lee S, et al. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs. Circulation. 1998;97:2331-2337.
38.
39. Swedberg K, Pfeffer M, Coen-Solal A et al. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan results from the CHARM study. J Am Coll Cardiol 2004;43(Suppl A).
40.
41. Choudhury A, Varughese G, Lip G. Targeting the Renin Angiotensin Aldosterone System in Atrial Fibrillation: a shift from electrical to structural therapy? Exp Opin Pharmacother 2005.
42.
43. Nakashima H, Kumagai K, Urata H. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-2617.
44.
45. Borghi C., Bacchelli S., Esposti D.D., Ambrosioni E.A review of the angiotensin converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. - Expert Opinion on Pharmacotherapy, 2004; 5 (9):1965-1977.
46.
Review
For citations:
Tatarskyi B.A. Application of an angiotensin)converting enzyme inhibitor zofenopril in patients with paroxismal form of atrial fibrillation. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2007;13(3):197-201. (In Russ.) https://doi.org/10.18705/1607-419X-2007-13-3-197-201
Views:
930
Email this article 